Patents Assigned to Arcutis, Inc.
  • Inhibition of crystal growth of roflumilast
    Patent number: 10940142
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: March 9, 2021
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Inhibition of crystal growth of roflumilast
    Patent number: 10105354
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 23, 2018
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Inhibition of crystal growth of roflumilast
    Patent number: 9907788
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: March 6, 2018
    Assignee: Arcutis Inc.
    Inventor: David W. Osborne
  • Inhibition of crystal growth of roflumilast
    Patent number: 9884050
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 6, 2018
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne